Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119858 | 1.00 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL2609244 | 0.90 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL12929226 | 0.86 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GAALMNAPOLB | |
| SCHEMBL523375 | 0.81 | PDK1 (0.46) | SMN1; SMN2ARMEN1KMT2ARBP4 | |
| SCHEMBL523374 | 0.81 | PDK1 (0.46) | SMN1; SMN2ARMEN1KMT2ARBP4 | |
| SCHEMBL13685998 | 0.79 | AR (0.47) | ALDH1A1SMN1; SMN2GAALMNAAR | |
| SCHEMBL1051707 | 0.79 | AR (0.47) | ALDH1A1SMN1; SMN2GAALMNAAR | |
| SCHEMBL16556712 | 0.78 | AR (0.43) | ALDH1A1SMN1; SMN2LMNAPOLBL3MBTL1 | |
| SCHEMBL17378666 | 0.76 | AR (0.44) | ALDH1A1SMN1; SMN2LMNAL3MBTL1AR | |
| SCHEMBL1048265 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2GAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456773-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | Apotex Pharmachem Inc. (CA) | 2012-05-30 | — | — | EP | claimed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | claimed |
| WO-2011009203-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-27 | — | — | WO | claimed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | claimed |
| US-8378143-B2 | Methods of making Efavirens and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2013-02-19 | — | — | US | disclosed |
| EP-2456773-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | Apotex Pharmachem Inc. (CA) | 2012-05-30 | — | — | EP | disclosed |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| WO-2011009203-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009203-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-27 | — | — | WO | disclosed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | disclosed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | disclosed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | ALDH1A1 290/4885SMN1; SMN2 3125/4885GAA 992/4885 |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | ALDH1A1 223/4885SMN1; SMN2 3009/4885GAA 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.